Evaluation of Carbapenemase resistance in Pseudomonas aeruginosa and Enterobacteriaceae family isolated from clinical specimens by using phenotypic methods in 2014-2015

Abstract

Introduction: Carbapenems is on second line therapy of multidrug resistant Pseudomonas aeruginosa infections and are the last defense line in critical infections Enterobacteriaceae family but Carbapenems resistance is increased so there are some problems when Carbapenems resistance is increased. Therefore, a new study about carbapenem resistance is necessary. Materials and Methods: This study collected 196 isolated bacteria of Pseudomonas aeruginosa and Enterobacteriaceae family from Hospitals patient of Tehran and evaluates them by phenotypic and biochemical methods. Also, the researcher studies the disk diffusion method and use it to determine antibiotic sensitivity of all bacteria according to the CLSI standard table. Results: From the total of 196 bacteria collected, the resistance to Meropenem is %39.79 and Imipenem is %45.91 and 30.10 percent to Meropenem and Imipenem resistance so that the percent resistance of bacteria is as follows: Pseudomonas aeruginosa resistance to Meropenem is %39.62 and Imipenem is %43.39. Meropenem and Imipenem resistance in Enterobacteriaceae family are as follows: Salmonella resistance to Imipenem and Meropenem is %0 and %50, Citrobacter koseri the resistance to Imipenem and Meropenem %0 and %50, Citrobacter freundii Meropenem resistance of %28.57 and Imipenem %28.57, Escherichia coli resistance to Meropenem %39.70 and Imipenem %47.05, Klebsiella oxytoca resistance to Meropenem %46.6 and %40 Imipenem and Meropenem resistance Klebsiella pneumoniae %34.14 and Imipenem %53.65, respectively. Conclusion: There is an increasing resistance to Meropenem and Imipenem antibiotics in treatment of Pseudomonas aeruginosa and Enterobacteriaceae family in our country. Hence, it should be properly and reasonably use these antibiotics.